Advertisement

Appropriate dosing of the individual direct oral anticoagulants in atrial fibrillation: Differences in the questions to be answered

Published:January 07, 2022DOI:https://doi.org/10.1016/j.ejim.2022.01.014

      Keywords

      Direct oral anticoagulants; Apixaban; Dabigatran; Edoxaban; Rivaroxaban
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Steffel J.
        • Collins R.
        • Antz M.
        • Cornu P.
        • Desteghe L.
        • Haeusler K.G.
        • et al.
        2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
        Europace. 2021; 23: 1612-1676https://doi.org/10.1093/europace/euab065
        • Rubboli A.
        Horizontal vs. vertical dose reduction of direct oral anticoagulants in patients with non-valvular atrial fibrillation: definition and implications for practice.
        Eur J Intern Med. 2019; 62: e11-e12https://doi.org/10.1016/j.ejim.2019.01.005
      1. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000829/human_med_000981.jsp.

        • Steinberg B.A.
        • Shrader P.
        • Thomas L.
        • Ansell J.
        • Fonarow G.C.
        • Gersh B.J.
        • et al.
        ORBIT-AF investigators and patients. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry.
        J Am Coll Cardiol. 2016; 68: 2597-2604https://doi.org/10.1016/j.jacc.2016.09.966
        • Camm A.J.
        • Cools F.
        • Virdone S.
        • Bassand J.P.
        • Fitzmaurice D.A.
        • Fox K.A.A.
        • et al.
        GARFIELD-AF investigators. Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants.
        J Am Coll Cardiol. 2020; 76: 1425-1436https://doi.org/10.1016/j.jacc.2020.07.045